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Background: An accurate method that can diagnose and predict lupus and its neuropsychiatric manifestations
is essential since currently there are no reliable methods. Autoantibodies to a varied panel of antigens in the
body are characteristic of lupus. In this study we investigated whether serum autoantibody binding patterns on
random-sequence peptide microarrays (immunosignaturing) can be used for diagnosing and predicting the onset of
lupus and its central nervous system (CNS) manifestations. We also tested the techniques for identifying potentially
pathogenic autoantibodies in CNS-Lupus. We used the well-characterized MRL/lpr lupus animal model in two studies
as a first step to develop and evaluate future studies in humans.
Results: In study one we identified possible diagnostic peptides for both lupus and altered behavior in the forced
swim test. When comparing the results of study one to that of study two (carried out in a similar manner), we further
identified potential peptides that may be diagnostic and predictive of both lupus and altered behavior in the forced
swim test. We also characterized five potentially pathogenic brain-reactive autoantibodies, as well as suggested
possible brain targets.
Conclusions: These results indicate that immunosignaturing could predict and diagnose lupus and its CNS
manifestations. It can also be used to characterize pathogenic autoantibodies, which may help to better
understand the underlying mechanisms of CNS-Lupus.
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Systemic lupus erythematosus (SLE) is an autoimmune
disease that affects many organs including the joints,
kidneys and brain [1]. Some of the symptoms include
arthritis, rashes, seizures, and psychoses. One of the
characteristics of lupus is the detection of autoantibodies
to numerous different antigens in the body [2,3]. The
brain is one of the affected organs, causing neuropsychi-
atric manifestations in 31% to 70% of lupus patients,
resulting in cognitive impairment and psychoses [4-7].
We have hypothesized that there are brain reactive auto-
antibodies that bind to integral membrane proteins of
the brain and this interaction is partly responsible for
some of the neuropsychiatric manifestations seen in
lupus [8,9]. These BRAA can enter the brain through in-
creased permeability of the blood–brain barrier as lupus* Correspondence: swilli4@asu.edu
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unless otherwise stated.progresses or are produced in the brain once antibody
producing cells enter the brain [10].
Our model of lupus is the MRL/lpr mice (Jackson Lab,
Bar Harbor, ME). These mice develop lupus symptoms
after 2 months of age and have 50% mortality at about
5–6 months of age. The MRL/lpr have manifestations
similar to humans including rashes, swollen joints and
neurobehavioral manifestations [11,12]. A mutant of the
fas gene, the lpr gene, is thought to help accelerate
lupus-like symptoms in these mice. Because of the simi-
larity to human lupus, the MRL/lpr mouse is an excel-
lent model of SLE and has been used by many other
researchers as their model of choice [11,12].
The manifestations of lupus resemble the manifesta-
tions of other diseases, making accurate diagnosis diffi-
cult. Physicians use a set of 11 different criteria and
patients must satisfy 4 out of 11 to be diagnosed as hav-
ing lupus [13]. Antinuclear antibodies and anti-DNA
autoantibodies have been used as some of the markers
for the diagnosis of lupus [14]. However, these markersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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rectly diagnose and even predict the onset of lupus and
its CNS manifestations is of high importance due to the
current inability to do so [14].
We have multiple goals in this report. The first goal is
to diagnose lupus, and CNS lupus, using sera, in a reli-
able and rapid manner. We tested the idea that we could
do this using immunosignaturing [15]. There is mount-
ing evidence that this technique may be useful to diag-
nose other CNS diseases such as Alzheimer’s [16,17].
Our second goal was to predict lupus onset, and specific
CNS manifestations, pre-symptomatically. There are low
concentrations of autoantibodies present in the sera
even before clinical signs of lupus. If some autoanti-
bodies predict the onset of lupus, and specific CNS
manifestations, detection using immunosignaturing is
possible. Identification of potential predictive peptides
for specific CNS manifestations would be unique to this
study. We and others have used the forced swim test as a
measure of depressive like behavior in the MRL/lpr
model [1,2,18]. In the current study we utilized this test
to indicate CNS dysfunction, however, it should be noted
that this test is only one measure and therefore does not
represent all CNS dysfunction. It is expected that other
peptide subsets generated using our microarray tech-
niques will probably correlate with other measures of
CNS dysfunction.
Our third goal was to obtain preliminary information
on the utility of this technique for future studies in char-
acterizing the antigenic targets of potentially pathogenic
brain-reactive autoantibodies. The random-sequence pep-
tide microarray was used to identify peptides reactive to
antibodies against BRAA. Peptide sequences were analyzed
using the Guitope computer program [19] to identify po-
tential protein targets. As an initial test, we created five
monoclonal BRAA from an MRL/lpr mouse with behav-
ioral dysfunction to identify likely targets of these mono-
clonal BRAA.
The latter is important because determining the iden-
tity of BRAA targets will allow us to better understand
their potential functional effects, and whether they may
be mediating neuropsychiatric manifestations. These
might also provide new therapeutic targets. For example,
one group of researchers has found an autoantibody that
reacts with double-stranded DNA and the NMDA re-
ceptor [20]. This autoantibody resulted in cognitive defi-
cits in their murine model, suggesting that this NMDA
receptor autoantibody could be responsible for CNS
manifestations [21]. Another researcher found an auto-
antibody that is cross-reactive with the dynamin-1 pro-
tein that also altered the behavioral performance of their
autoimmune murine model in comparison to controls
[22]. These research findings are, however, relatively ran-
dom. Our techniques should provide a reliable methodfor identifying such potentially pathogenic BRAA and
their targets.
Overall, our microarray technology should be more ac-
curate in diagnosing and predicting lupus and its CNS
manifestations, and allow for the optimum identification
of potentially pathogenic BRAA and their target anti-
gens. We were using a well validated animal model in
this study in order to see if future studies with humans
are warranted. We believe that our findings warrant hu-
man studies.
Methods
Animals
We used female MRL/lpr, MRL/mpJ (develops lupus-
like disease at about 12 months of age) and C3H/HeJ
mice. Females were employed instead of males since in
humans there is a sex-related difference where onset is
more predominant in females, however for the MRL/lpr
mice no overt sex-related differences exist, although
there is some suggestion that a propensity does exist at
the genetic level [23]. In Study 1, we used 3–6 MRL/lpr,
MRL/mp and C3H/HeJ at 4 months and in Study 2 we
increased the number to 9–10 MRL/lpr and MRL/mp at
1.5 and 4 months. Blood was collected at 1.5 and
4 months in Study 2, but only at 4 months in Study 1.
The mice were obtained from Jackson Laboratory (Bar
Harbor, ME) and individually housed under standard
conditions for both studies. The light cycle was from
6:00 A.M. to 6:00 P.M. They were given food and water
ad libitum. In both studies the behavioral tests were per-
formed similarly at 8:00 P.M.
The mice were sacrificed with an intraperitoneal (IP)
injection of Nembutal sodium solution. The blood was
collected via cardiac exsanguination and allowed to co-
agulate in microcentrifuge tubes. The tubes were centri-
fuged for 10 minutes at 8500 rpm (5200 × g). The serum
was aliquoted and frozen at −50°C. The spleen weight
was divided by the body weight of that mouse to control
for differences in body weight.
Animals were maintained in university facilities fully
accredited by AAALAC and are registered with the
USDA APHIS (Registration # 86-R-0002). An assurance
is on file with the Office for Laboratory Animal Welfare
(#3217-01). Animal husbandry programs and protocol
review are in compliance with NIH and USDA standards.
The protocols used in the animal studies were approved
by the Institutional Animal Care and Use Committee at
Arizona State University.
Behavioral testing
Our battery of behavioral tests included the forced swim
test and the sucrose preference test. The forced swim
test is used to analyze anti-depressants by measuring
float time and the sucrose preference test can assess
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through quantifying consumption. Both tests have been
used with the MRL/lpr mice to indicate emotional dys-
function [1]. The sucrose preference test has been de-
scribed previously [2], except the mice were given 7 ml of
the 4% sucrose solution for 1 hour each day for three
days in the testing phase. The forced swim test has also
been previously described [2]. The MRL/lpr mice are
expected to have high float times and low sucrose con-
sumption. In this manuscript, the results of the sucrose
preference test were determined to be inconclusive and
were not reported.
Immunological assessment
Integral membrane protein preparation and ELISA for
anti-DNA and BRAA
The technique to extract integral membrane proteins
from the brain has been previously described [24]. A
two month C3H/HeJ brain was used in the BRAA
ELISA. Once the integral membrane proteins were ex-
tracted they were suspended in phosphate buffered sa-
line (PBS) and protein concentration determined using
the BCA Assay Kit (Pierce, USA). Anti-DNA and brain-
reactive autoantibody levels were determined using pre-
viously described ELISA protocols [2,25,26]. The optical
density of the control wells (the even wells) were sub-
tracted from the optical density of the odd wells to give
an S-value that showed the levels of anti-DNA anti-
bodies (or BRAA). Some S-values may be negative, since
the S-values are a relative measure.
Microarray analysis
Microarrays containing 10,000 random-sequence 20-mer
peptides were obtained from the Center for Innovations in
Medicine, Biodesign Institute, Arizona State University
[15]. Manufacture of the arrays were described previously
[27]. Microarrays were processed in a Tecan HS 4800 Pro
(Tecan, Mannedorf, Switzerland). The hybridization station
performed these steps: arrays were pre-washed in PBS buf-
fer and exposed to a 1:500 dilution of serum or a 10nM
purified monoclonal antibody solution and detected with
5nM biotinylated anti-idiotype secondary antibody, which
was then exposed to 5nM streptavidin conjugated to
Alexafluor 647 fluorophore (Alexafluor 555 fluorophore
for mice sera). Arrays were washed to remove any un-
bound material and scanned in a Perkin Elmer ScanArray
laser scanner at 650 nm and 10um resolution. Tiff images
were aligned to the corresponding .gal file and a .gpr file
was produced containing the intensity values correspond-
ing to the appropriate peptide. Typical technical reprodu-
cibility was >0.80 Pearson’s Correlation Coefficient for all
10,000 peptides.
Each peptide on the microarray was synthesized and
quality tested by Alta Biosciences (Birmingham, UK). Thesequence, mass spectrometry of each peptide, and other
chemical characteristics are known. No peptide with <80%
purity by mass spectrometry was used in these arrays. Our
microarray data have been deposited in GEO under acces-
sion numbers GSE57388 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE57388) and GSE57389 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57389).
Monoclonal antibody production
Monoclonal BRAA were produced using a ClonaCell®-
HY Hybridoma Kit purchased from STEMCELL Tech-
nologies (Vancouver, Canada). The protocol used has been
described in the manual. Mouse myeloma cells (Sp2/0-
Ag14 – ATCC (USA)) were fused with spleen cells from
MRL/lpr #2. Cell viability was determined using trypan
blue. Visible colonies on the petri dishes were plated in
96-well plates and tested for the presence of BRAA using
ELISAs and if positive were transferred to 24-well plates.
If the cells were still positive, they were cultured in petri
dishes and then stored at −80°C.
Western blotting
The Western blotting protocol has been described previ-
ously [2]. The blots were cut into strips and incubated
with different primary antibodies. For some of the strips
more wash steps were necessary to better see the bands.
The size of the bands was calculated using a linear plot
of the molecular weights of the protein marker and dis-
tance traveled (Fermentas, USA).
Immunohistochemistry
Mid-brain sections from a 4 month C3H/HeJ control
mouse were used to determine the binding location of
the 5 different monoclonal BRAA as well as sera from
LPR #2 (the mouse used to create the monoclonals).
The immunohistochemistry technique used was previ-
ously described [2]. The slides were observed using a
Leitz Laborlux 12 microscope and pictures were taken
using a Nikon camera at 4× and 250× magnification.
Statistics
Analytical methods for conventional expression mi-
croarrays were used for the immunosignature micro-
arrays and no unusual biases were noted. The arrays
yielded 14% average slide-to-slide Coefficient of Vari-
ance, and a 1.3-fold minimum detectable fold-change
at the 95th percentile, near the reproducibility of typ-
ical commercial microarrays. All experiments were done
with triplicate technical and triplicate biological repli-
cates (9 samples per condition). Tests were done on
pooled sera from replicate mice but each mouse was also
analyzed independently to determine mouse-to-mouse
variance as well as the robustness and representative na-
ture of each immunosignature. Numerical data from the
Figure 2 Serum BRAA Levels for Study 1. ANOVA of the BRAA
levels revealed a significant difference between the groups (F = 14,
p < 0.005). Post-hoc analysis at p < 0.004 showed that the 4 month
MRL/lpr had significantly greater BRAA levels in comparison to the
MRL/mp and C3H/HeJ.
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Palo Alto, CA) or R (CRAN GNU open-source) for
analysis. Slides were median normalized and log-10
transformed for analysis. Statistics typically used stand-
ard t-test between case and control using the Benjamini
and Hochberg False Discovery Correction Rate set at 5%.
Technical replicates were averaged prior to conducting the
t-test.
Statistical analysis for Figures 1A, 1B, 2, 3, 4, 5
and 6, Additional file 1: Figure S2, Additional file 2:
Figure S3 and Additional file 3: Figure S4 were deter-
mined using 1-way ANOVA and LSD Post-Hoc analysis
(SPSS 16.0 and PASW Statistics 18). Figure 7 was plotted
using Microsoft Excel 2007. Microsoft Excel was also used
to calculate the mean and standard deviation (SD) for the
control C3H/HeJ group and the binding ratios for each of
the test groups versus the C3H/HeJ mice. The peptides in
the groups were kept for further analysis only if their bind-
ing ratios were above the mean plus 0.25 SD, mean plus
1.5 SD or mean plus 2.5 SD depending on the peptide
set (the cutoff specific to each peptide set is listed in
the Results section).
To determine possible matches between the peptides
and potential protein targets, the peptides were aligned
individually to all proteins in the mouse proteome, using
a gapless local alignment. Alignment scores were summedA
Figure 1 Immunological assessment for Study 1. (A) Three randomly se
assessments (the numbers next to each dot represent the mouse number)
different between the groups (F = 112.953, p < 0.001) and using post-hoc ana
antibody levels compared to controls (measured at 1:800 serum dilution). (B)
groups (F = 18.365, p < 0.003) and post-hoc analysis at p < 0.007 revealed that
weight) compared to the MRL/mp and C3H/HeJ. In the box plot the middle l
bottom of the box is the 25th percentile.along each protein and proteins were ranked by their
maximum score. The same numbers of peptides were
randomly selected from the entire 10 K to estimate the
null distribution of these scores. An empirical one-
sided p-value was reported based on the percentage ofB
lected mice from each of the groups were used for immunologic
. ANOVA showed that anti-DNA autoantibody levels was significantly
lysis at p < 0.001 the 4 month MRL/lpr had significantly greater anti-DNA
For the spleen weights there was a significant difference between the
the 4 month MRL/lpr had significantly greater spleen weights (per body
ine is the 50th percentile, the top of the box is the 75th percentile and the
Figure 3 Forced Swim Test Study 1 – Group Separation within
the MRL/lpr by Neurobehavioral Manifestations. The five MRL/lpr
mice were split into two groups with mice 2, 3 and 4 grouped as
high floaters and 1 and 5 were low floaters. There was an overall
significant difference between the groups (F = 9.2, p < 0.008). Post-hoc
analysis at p < 0.010 revealed that the MRL/lpr high floaters were
significantly different from the MRL/lpr low floaters, the MRL/mp and
C3H/HeJ. The MRL/lpr low floaters were not significantly different from
the MRL/mp and C3H/HeJ.
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vs. the randomly selected peptides. This analysis was
performed using an application called Guitope [19].
Halperin and colleagues previously demonstrated that a
similar method of aligning random-sequence peptidesAnti-DNA Autoan
Figure 4 Immunological Assessment for Study 2 – Anti-DNA Autoanti
MRL/lpr (N = 9-10) and MRL/mp at 1.5 and 4 months of age. ANOVA r
(F = 44.067, p < 0.001) and LSD post-hoc analysis at p < 0.001 showed that th
compared to the 4 M MRL/mp, 1.5 M MRL/lpr and 1.5 M MRL/mp.selected from array experiments has some value in pre-
dicting epitopes [28].
Results
Goal 1 (Sections 1 and 2): identify possible diagnostic
peptides of lupus and CNS-lupus
Section 1: study 1 - identify possible diagnostic peptides of
lupus and its CNS manifestations
In this section Study 1 was designed to identify possible
“diagnostic” antibodies in the sera of 4 month MRL/lpr
mice based on the binding intensities of the different
peptides compared to the controls (MRL/mp and C3H/
HeJ mice). We also identified possible diagnostic pep-
tides of altered behavior in the forced swim test. We
called these “diagnostic peptides” since at 4 months the
MRL/lpr mice are expected to have lupus-like disease. We
used the MRL/mp as a genetic control for the MRL/lpr
since they are genetically identical (without the lpr gene)
but have late-onset autoimmunity.
Possible diagnostic peptides for lupus
Immunological assessment and disease activity We
previously showed that increased serum anti-DNA auto-
antibody levels and spleen weights correspond to disease
activity [29,30]. Using 3 randomly selected mice from
each group (Figure 1A), ANOVA revealed that anti-
DNA autoantibody levels were significantly different be-
tween the groups (F = 112.953, p < 0.001). LSD post-hoc
analyses at p < 0.001 showed that the MRL/lpr had sig-
nificantly greater anti-DNA autoantibodies in comparisontibody Levels
body Levels. Anti-DNA autoantibody levels was measured for the
evealed that there was a significant difference between the groups
e 4 M MRL/lpr had significantly greater anti-DNA autoantibody levels
BRAA Levels
Figure 5 Immunological Assessment for Study 2 – BRAA Levels. BRAA levels was measured and ANOVA revealed that there was a significant
difference between the groups (F = 9.746, p < 0.001). Utilizing post-hoc analysis at p < 0.001 the 4 M MRL/lpr had significantly greater BRAA levels
compared to the 4 M MRL/mp, 1.5 M MRL/lpr and 1.5 M MRL/mp.
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(Figure 1B), ANOVA showed that there was a significant
difference between the groups (F = 18.365, p < 0.003) and
post-hoc analysis at p < 0.007 revealed that the MRL/lpr
mice had greater spleen weights compared to the controls.
The increase in both spleen weights and anti-DNA auto-
antibody levels indicated that lupus was progressing.Forced Swim Test
Figure 6 Forced Swim Test Study 2 – Group Separation within MRL/lp
was re-plotted to separate the 4 M MRL/lpr into two groups (3 and 4) base
2 – 1.5 M MRL/mp, 3 – 4 M MRL/lpr low floaters, 4 – 4 M MRL/lpr high floa
group 4 included mice 1, 2, 4, 8, 9 and 10. ANOVA revealed that there was
post-hoc analysis at p < 0.001 showed that the 4 M MRL/lpr low floaters we
4 M MRL/lpr high floaters were significantly different from all groups.Microarray analysis revealing possible diagnostic
peptides of lupus The sera samples from all nine mice
were analyzed in triplicates using microarray technology
to ensure consistency. Additional file 4: Figure S1 illus-
trated a representative slide from each group. Additional
file 4: Figure S1A and 1B were the no primary control
and C3H/HeJ slides, respectively, and little reactivity wasr by Neurobehavioral Manifestations. The forced swim test data
d on their float times. The groups were as follows: 1 – 1.5 M MRL/lpr,
ters and 5 – 4 M MRL/mp. Group 3 included mice 5, 6 and 7 and
a significant difference between the groups (F = 30.253, p < 0.001) and
re only significantly different from the 4 M MRL/lpr high floaters. The
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Figure 7 BRAA ELISA Results of our Potential Pathogenic Monoclonal BRAA. The graph showed the reactivity of the five potential clones
(above 0.1 OD) and MRL/lpr#2. No binding was detected in the control.
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MRL/lpr serum reactivity. The MRL/mp had lower re-
activity than the MRL/lpr (Additional file 4: Figure S1D).
To determine possible diagnostic peptides of lupus, we
divided the average binding intensities of the 4 month
MRL/lpr by the average binding intensities of the
4 month C3H/HeJ, creating a binding ratio for each pep-
tide. This picked out antibodies favoring autoimmune
mice, but to be more conservative in our selection, we se-
lected only those peptides whose ratios were greater than
the mean plus 1.5 SD of the binding intensities of the
4 month C3H/HeJ. There were 193 possible diagnostic
peptides of lupus.
Possible diagnostic peptides of altered behavior in forced
swim test
Brain-reactive autoantibody levels BRAA level was used
to measure CNS involvement, which has been discussed
previously [2,9]. ANOVA (Figure 2) revealed that there
was a significant difference between the groups (F = 14,
p < 0.005). Post-hoc analysis at p < 0.004 showed that the
MRL/lpr had greater levels compared to the controls.
Behavioral dysfunction in the forced swim test In the
forced swim test, a significant difference in float time
was detected between the groups (Additional file 1:
Figure S2) (F = 12.068, p < 0.008). Post-hoc analysis at
p < 0.007 revealed increased float times for the MRL/lpr
compared to the MRL/mp and C3H/HeJ, indicating CNS
involvement (possibly emotional dysfunction) [1,11].
Group separation within MRL/LPR for forced swim
test Behavioral heterogeneities have been reported within
the MRL/lpr group, i.e., dissimilarity in performancedepending on the test [1]. The 4 month MRL/lpr had vary-
ing anti-DNA and BRAA levels and diverse binding pat-
terns. Because of these differences, we may be able to
identify peptides bound by autoantibodies that may be
diagnostic of certain neuropsychiatric manifestations.
To test this, we first grouped the mice according to
their behavior in the forced swim test and then looked
for differences in peptide binding. MRL/lpr #2, #3 and
#4 were grouped as high floaters and MRL/lpr #1 and #5
were low floaters (Figure 3). There was an overall signifi-
cant difference between the groups (F = 9.2, p < 0.008)
and post-hoc analysis at p < 0.010 revealed statistically
significant differences between the MRL/lpr high floaters
compared to the low floaters, MRL/mp and C3H/HeJ.
There were no significant differences between the MRL/
lpr low floaters and the MRL/mp and C3H/HeJ.
The MRL/lpr were also regrouped based on their anti-
DNA autoantibody levels (Additional file 2: Figure S3).
The breakdown was similar to the forced swim test
(Figure 3). There was a significant difference between the
groups (F = 91.176, p < 0.001) and post-hoc analysis at
p < 0.004 revealed significant differences between the
4 month MRL/lpr with greater anti-DNA antibody levels
compared to the MRL/lpr with lower anti-DNA autoanti-
body levels, the MRL/mp and C3H/HeJ. Significant dif-
ferences were detected between the MRL/lpr with lower
anti-DNA autoantibody levels and the MRL/mp and C3H/
HeJ. This suggests that disease activity (other than BRAA)
may be contributing to these behavioral manifestations.
Microarray analysis revealing possible diagnostic
peptides of altered behavior in the forced swim
test We ran microarray analyses based on the grouping
in Figure 3 and selected peptides where the 4 month
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the 4 month MRL/lpr low floaters. Next, the binding inten-
sities of these peptides were divided by their respective
4 month C3H/HeJ binding intensities. We selected only
peptides with greater binding intensities than the mean
plus 1.5 SD of the binding intensities of the C3H/HeJ.
There were 261 possible diagnostic peptides of altered be-
havior in the forced swim test.
Section 2: study 2 - further identify possible diagnostic
peptides of lupus and CNS-lupus
In Study 2 we could better suggest which peptides may
be diagnostic of lupus and its CNS involvement by com-
paring the peptide sets generated in Study 1 to those
generated in Study 2. Altered behavior in the forced
swim test assessed CNS involvement.
Identifying possible diagnostic peptides of lupus
Disease activity ANOVA of the quantified anti-DNA
autoantibody levels for the 9–10 MRL/lpr and MRL/mp
revealed that there was a significant difference between
the groups (F = 44.067, p < 0.001). LSD post-hoc analysis
at p < 0.001 showed that the 4 month MRL/lpr had sig-
nificantly greater anti-DNA autoantibody levels com-
pared to the 1.5 and 4 month MRL/mp and 1.5 month
MRL/lpr (Figure 4), signifying disease activity [29].
Microarray analysis identifying possible diagnostic
peptides of lupus The same type of analysis performed
in section 1b of Study 1was repeated here using the
4 month MRL/lpr and the 4 month C3H/HeJ from
Study 1. There were 172 possible diagnostic peptides de-
tected in Study 2. When comparing the 193 peptides
from Study 1 to the 172 peptides from Study 2, 58 were
in common. Since these 58 peptides were reoccurring,
this suggests that these 58 peptides may be effective at
diagnosing lupus (Table 1).
Identifying possible diagnostic peptides of altered behavior
in the forced swim test
Brain-reactive autoantibody levels ANOVA revealed
that there was a significant difference in BRAA levels be-
tween the groups (F = 9.746, p < 0.001) and LSD post-hoc
analysis at p < 0.001 showed that the 4 month MRL/lpr
had greater BRAA levels compared to the 1.5 and 4 month
MRL/mp and 1.5 month MRL/lpr (Figure 5).
Behavior testing In the forced swim test, there was a
significant difference between the groups (F = 11.057,
p < 0.001) and post-hoc analysis at p < 0.05 revealed
that the 4 month MRL/lpr floated significantly more than
the 1.5 and 4 month MRL/mp and 1.5 month MRL/lpr
(Additional file 3: Figure S4). This indicated that the
4 month MRL/lpr were displaying altered behavior.Group separation within MRL/lpr based on the forced
swim test Of the nine mice in the 4 month MRL/lpr
group, numbers 5, 6, and 7 were grouped as low floaters
and the others were classed as high floaters. There was
an overall significant difference between the groups
(F = 30.253, p < 0.001) and post-hoc analysis at p < 0.001
revealed that the 4 month MRL/lpr high floaters floated
significantly more than all the other groups (Figure 6).
Microarray analysis validating diagnostic peptides of
altered behavior in forced swim test Similar analysis
performed in section 2d of Study 1 was carried out here
and 190 possible diagnostic peptides of altered behavior
in the forced swim test were detected. A comparison of
both peptide sets uncovered 39 in common suggesting
that these 39 peptides are likely diagnostic peptides of
altered behavior in the forced swim test (Table 2).
Goal 2 (Sections 3 and 4): identify possible predictive
peptides of lupus and CNS-lupus
Section 3: identifying possible predictive peptides of lupus
The 4 month MRL/mp from Study 1 and the 1.5 month
MRL/lpr from Study 2 were useful in determining possible
predictive peptides of lupus since they are lupus-prone but
displayed no detectable disease activity (Figures 1A, 1B
and 4). Even though the binding intensities were always
higher for the 4 month MRL/lpr, the 1.5 month MRL/lpr
and 4 month MRL/mp had greater binding intensities for
some peptides when compared to the C3H/HeJ control.
We first went back to Study 1 and compared the bind-
ing intensities of the 4 month MRL/mp to 4 month
C3H/HeJ to identify possible predictive peptides of lupus.
Peptides were selected only if their ratios were greater
than the mean plus 0.25 SD of the binding intensities of
the C3H/HeJ. From this, 143 possible predictive peptides
of lupus were identified. In Study 2, we did this same type
of analysis using the 1.5 month MRL/lpr but chose pep-
tides where their ratios were greater than the mean plus
1.5 SD of the binding intensities of the C3H/HeJ. In
Study 2, 518 possible predictive peptides of lupus were
identified. The cut off value was lower for the 4 month
MRL/mp in Study 1 because they would develop overt
signs of lupus-like disease at a much later time point than
the MRL/lpr (develop symptoms shortly after 2 months).
When comparing the 143 possible predictive peptides of
lupus from Study 1 to the 518 possible predictive peptides
from Study 2, 18 peptides were in common and so these
18 peptides were identified as likely predictors of lupus
(Table 3).
Section 4: identifying possible predictive peptides for altered
behavior in the forced swim test
The 1.5 month MRL/lpr from Study 2 were split into
two groups identical to the grouping in Figure 6 for the
Table 1 Diagnostic peptides of lupus
Diagnostic peptide sequence
of lupus
Binding ratios In common with
predictive peptides
of lupus
In common with
diagnostic peptides
of CNS-lupus
In common with
predictive peptides
of CNS-lupus
Study 1 4MLPR/
4MC3H
Study 2 4 M LPR/
4MC3H
ADGSNWAARHWIPRMPRGSC 3.404555813 2.332923454
AMSFHRGWDRKYRMSNIGSC 2.599608572 2.484332734 √
AQLGMYGVYRPVEIWPDGSC 2.872747926 2.519910261 √ √
ATDKTRFHFLYDYIRSNGSC 2.399571763 2.880058556
DDTLYNAHKHLKWFGFIGSC 2.515491313 3.037141329 √
EATGNDWVITRGGMRRYGSC 2.556966833 3.171502541
EMNNGRFHRWAQQERHPGSC 2.880990297 2.507493739
EMSWPRKPWRSKYYHEIGSC 2.353443025 2.435039315 √ √
ENILPTGRDRVAGWYRYGSC 2.825255829 2.675812354 √
EPKLWFKPRRGGYRHRHGSC 2.679076813 2.434485702 √
ERIYRDHFIHEHKANIIGSC 2.389911067 2.665777953 √
EWYYDPRGGTGSFYMRTGSC 2.826268307 3.144085944 √
FNRDHREFFEHFGFDEPGSC 4.422628739 2.314403551 √
FPGDRRSGRAFPEVRWRGSC 2.66924554 2.635674506 √
FTLMTGKKMIVWDWQRDGSC 2.564037604 2.381362551 √
FWEHHVFHSSRRDGWASGSC 2.951177541 2.464272834
GLVSRIPSVPKHDEWTFGSC 2.38601487 2.329539073 √
GRVPQDFNTPSFDRVFWGSC 2.513399666 2.788409089 √
GWLKAMGPFPWGRLVQNGSC 2.681235945 3.008923213 √ √
IEAMGPSQRYRGRYELIGSC 2.377783579 2.371993113
IGQRLKGKDENIRFENFGSC 2.347244686 3.594919118 √ √
ILDRRETAWNEHFSKFRGSC 2.781744911 2.979425643 √
KAMSIHQLANPFDWHFWGSC 2.316559723 2.705671849
KGYSIRHTEHAWPDIYVGSC 2.579657821 3.104342319 √
KLLMTDFMAKWPRNGWYGSC 3.325866727 2.467180958 √ √
KQHPIYIAHFLGTIVKRGSC 2.850248411 2.447758339
KVDYVNQWARRRIFMAPGSC 2.933406801 2.826782754 √
KWLQTQLNSAMYYIRLYGSC 3.442674101 2.816729922
LAFAWKPDPWQSLVTKFGSC 3.276131888 2.698697705 √
LFSFKEPQPFMWNKWQQGSC 3.390564552 2.759114763
LRKISRGIWGMREAGEFGSC 2.476731381 3.603591875
MFARAHNFDWVKWPLNRGSC 2.705759435 2.921507814 √
MWMSWGWAMLWLNGMMQGSC 4.177408974 2.432118292
PLVHPWYPTYIPGRHNMGSC 3.630154471 2.495553997 √
PMLFWKWHRQLNQQGRRGSC 2.75721307 2.335852256 √ √
PNPEAWARSFKRWNRKFGSC 3.313709957 3.508821684 √
PSAWEWIPRNQHLNKFRGSC 3.112407959 2.391409291 √ √
PTWRLPPYTDPPKYWHPGSC 4.201093721 3.373945327
PYRFDWAALPLKKPMWRGSC 2.40624731 2.565057719 √
QKKPPDYRTWHHPFYNGGSC 2.604969331 2.754487673 √
QKRWLQLPRNLMWRRETGSC 2.664022568 2.529899901 √
QRKIFFNYKLHKIWFTAGSC 2.362843141 2.462441712
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Table 1 Diagnostic peptides of lupus (Continued)
QSHWFYDRTKDVYPGRHGSC 3.992759382 2.329563875 √
RAAMHESLKNWRVYREWGSC 2.388166554 2.725739509 √ √
RPAFDKFADSYWYPPNLGSC 2.471919459 2.483799875
RRLTKGIIRQYESQLWDGSC 2.38838007 3.049171397
RTIYRWSQGALSWYMDAGSC 2.443171562 2.802208961 √
SDQVIRGFKDVWQYKWFGSC 3.018394899 2.579167723
SRDAGLQYPYHRWLTGWGSC 2.452812911 2.732221588
SRLEQQHFATIPQIWYTGSC 2.462810107 2.571973953
SRQGLHYNLDGLKPIFPGSC 2.652106822 2.808739776 √
TLQRTWRRPLLEDLPWWGSC 5.695014524 3.855075257
VQERMHNRTWKRFGGSMGSC 2.754519694 2.496803929 √
WKPIWHSFHKRRPQILNGSC 2.50380818 2.372369774 √ √
WNGPEWKYSEKSKRILFGSC 2.445136421 2.433467124 √
WSYKYKKKQAWDWPWDPGSC 2.443311505 2.436968425 √
WTWPSIRFVKGEEYGRFGSC 2.991053751 2.626530982
YYNVQQVDRWVKLQWGLGSC 2.441114219 2.553038205 √
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here is that we know the future performance of these
1.5 month mice at 4 months and so can use them to de-
tect possible predictive peptides of this altered behavior.
We averaged the binding intensities for the 1.5 month
MRL/lpr in the 2 groups and chose peptides where the
binding intensities for the 1.5 month MRL/lpr high
floaters were greater than the 1.5 month MRL/lpr low
floaters. Then the binding intensities of these peptides
were divided by their respective binding from the
4 month C3H/HeJ. We selected only those peptides where
their ratios were greater than the mean plus 2.5 SD of the
4 month C3H/HeJ in order to be more conservative in
our choice. From this analysis we selected 96 possible pre-
dictive peptides of altered behavior in the forced swim test
(results not shown due to large number of peptides).
For each of the two-way tests noted above (case vs.
control), we performed a leave-one-out cross-validation
of the peptide array data using the selected ‘diagnostic’
peptides. We used Support Vector Machines as the clas-
sifier (using both SVM in GeneSpring 7.3.1 and in R
using the e1071 package). In no case did the cross-
validation report >3% error in classification.
Goal 3 (Sections 5 and 6): identify possible natural
antigenic targets
Section 5: characterizing potentially pathogenic
autoantibodies - identify possible natural protein matches
for our peptide sets
Using the sequences from each of the different peptide sets
and the Guitope program we suggested possible matches
to natural mouse proteins in Table 4.Section 6: characterizing five created monoclonal
brain-reactive autoantibodies
To suggest a possible use of random-sequence peptide
microarrays to help identify targets of BRAA, we charac-
terized five potentially “pathogenic” monoclonal BRAA
that were created from MRL/lpr #2. These BRAA (labeled
F9, G10, G4, D1 and D9) had S-Values above 0.1 OD on
the BRAA ELISA (Figure 7). MRL/lpr #2 displayed high
float time in the forced swim test (Figure 6), high levels of
serum BRAA (Figure 7) and intense fluorescence through-
out the brain (Figure 8A), including the cortex (Figure 8B
and 8E), amygdala (Figure 8C and 8F) and hippocam-
pus (Figure 8D). In the Western blotting results, which
will be discussed below, it should be noted that the
bands detected using the serum from MRL/lpr #2 were
of similar molecular weight to some of the bands de-
tected using the different monoclonal BRAA created from
this mouse (Figure 9).
Using our microarray technology (Guitope program
and peptide sequences) and Western blotting results,
we attempted to determine the mostly likely protein
target for the BRAA. In Table 5, we listed six possible
protein matches for each of the monoclonals (proteins
of interest have been highlighted and some will be dis-
cussed). Starting with D9, the approximate molecular
weight of its target was 54 kDa and binding was seen
all over the brain (Figure 10A), including the hippo-
campus (Figure 10B), cortex (Figure 10C) and amygdala
(Figure 10D). The yellowish/orange color was from pro-
pidium iodide staining while the green fluorescence is
from the specific antibody. One suggested target was
the D (1B) dopamine receptor (DRD5) with a molecular
Table 2 Diagnostic peptides of altered behavior in the forced swim test
Peptides sequence
Binding ratios In common
with predictive
peptides of lupus
In common
with diagnostic
peptides of lupus
In common with
predictive peptides
of altered behavior
in forced swim
Test study 1 4 M LPR
high Floaters/ 4MC3H
Study 2 4 M LPR high
Floaters/ 4MC3H
AGAFRERRYKPMMWLHVGSC 2.36 3.24
AGVRHKFHPYLMQFRRHGSC 2.48 2.44
AQLGMYGVYRPVEIWPDGSC 3.25 2.58 √ √
DDTLYNAHKHLKWFGFIGSC 2.71 3.21 √
EKFKRPRWPHLPFTHWDGSC 2.66 2.46
EPKLWFKPRRGGYRHRHGSC 2.87 3.02 √
EPSLQVITEYNINFLTIGSC 2.40 3.03 √
EQEDYDDDEEQEQDEDDGSC 2.37 2.36
ERNRRESDSKERKNYDHGSC 3.25 2.65
FPGDRRSGRAFPEVRWRGSC 3.27 2.76 √
GFHGPGMLGKTGRLSYGGSC 2.72 2.49
GLVSRIPSVPKHDEWTFGSC 2.45 2.49 √
GRVPQDFNTPSFDRVFWGSC 2.72 2.89 √
GWLKAMGPFPWGRLVQNGSC 2.93 3.10 √ √
IGQRLKGKDENIRFENFGSC 2.40 4.23 √ √
ILDRRETAWNEHFSKFRGSC 3.37 3.22 √
IPDGWLKNVYRVRVPWPGSC 2.64 2.34
IRFVAILVFVIIILIARGSC 2.34 2.95
KLLMTDFMAKWPRNGWYGSC 3.78 2.72 √
KTHHSMWKGRITHELFAGSC 2.45 2.52 √
KVDYVNQWARRRIFMAPGSC 3.27 3.35 √
LAFAWKPDPWQSLVTKFGSC 3.49 2.72
PMLFWKWHRQLNQQGRRGSC 3.13 2.44 √
PSAWEWIPRNQHLNKFRGSC 3.38 2.76 √ √
PYRFDWAALPLKKPMWRGSC 2.57 3.16 √
QKKPPDYRTWHHPFYNGGSC 3.04 3.01 √
QKRWLQLPRNLMWRRETGSC 2.92 2.77 √
QRVPIVKWLLWEPRALPGSC 2.99 2.48
QSAYHNHRMKWRKIGIEGSC 2.47 3.21
QSHWFYDRTKDVYPGRHGSC 4.79 2.64 √
RAAMHESLKNWRVYREWGSC 2.49 2.91 √ √
SRQGLHYNLDGLKPIFPGSC 2.77 3.34 √
SSELDFRKYSFYVHRPDGSC 2.74 2.54
TLNKRRSWRDGFTADEYGSC 2.31 2.39
VDARMETFYDMQYPYYLGSC 2.37 2.46
WKPIWHSFHKRRPQILNGSC 3.05 2.71 √
WRTKAAMKWQKYQREHRGSC 2.60 2.62
WSYKYKKKQAWDWPWDPGSC 2.93 2.74 √
YYNVQQVDRWVKLQWGLGSC 2.67 2.70 √
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We also detected a second band at ~39 kDa using the
supernatant from D9 (Figure 9). Other researchers havedetected a band at ~40 kDa when using anti-D (1B)
dopamine receptor antibody, so this receptor may be
the protein that we are detecting (Centonze et al., [31]).
Table 3 Predictive peptides of lupus
Peptide sequence
Binding ratios In common with
predictive peptides of
altered behavior in
forced swim test
In common with
diagnostic peptides of
altered behavior in
forced swim test
In common with
diagnostic peptides
of lupus
Study 1
MP/C3H
Study 2 1.5 M
LPR/C3H
DKFHYWMYMLYGINDKIGSC 2.12 2.34
DKLWKQIWTERHFMSHKGSC 1.57 4.30 √
DWDSRQINPHIIHHVGRGSC 1.41 2.78
EEHAHNKLFWWHRSRALGSC 1.61 2.52
EMSWPRKPWRSKYYHEIGSC 1.46 3.36 √ √
ENILPTGRDRVAGWYRYGSC 1.51 3.10 √
FNRDHREFFEHFGFDEPGSC 1.40 3.61 √
GYNYWIVEWDQDQWLMNGSC 1.39 2.76
HWKRRHKHKWPKRHPHKGSC 1.92 2.64
KIWAMRKPRYQYWNQPAGSC 1.41 2.86 √
KWDHGQNGLFPPMHYIPGSC 1.54 3.07
LEAHYKRSMHAQNWWEAGSC 1.41 2.60
QYLWWQMLKIEWNSTYAGSC 6.22 2.61
RHWYQDGSPLLAPVYKVGSC 1.48 3.07
SYQRENESDEEEKNNEDGSC 1.64 2.38
VEDNYGVTLRQPKYMGWGSC 1.41 2.36
WNAMGKWKAMVDKTGDFGSC 2.10 2.40
WNIHERHRFDQPYDYGHGSC 1.49 2.85
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tected with MRL/lpr #2 at approximately 54 kDa and
37 kDa.
Using D1, we detected two bands at 55 kDa and
95 kDa (Figure 9). We observed low levels of binding all
over the brain, but greater binding was seen in the cau-
doputamen and amygdala (Figure 11A). One possible
natural protein match could be the gamma-aminobutyricTable 4 Possible natural protein matches for the different pe
Peptide sets
58 diagnostic peptides of lupus
39 diagnostic peptides of altered behavior in the forced swim test
18 possible predictive peptides of lupusacid receptor subunit rho-1 (GABRR1). GABRR1 has a
molecular weight of ~56 kDa (The UniProt Consortium,
P24046). The 95 kDa band that was detected could be
some kind of modification to the protein or a dimer be-
tween this protein and another Gamma-aminobutyric acid
receptor subunit. On the antibody data sheet for GABRR1
antibody, two bands were detected at 55 kDa and >90 kDa
(ProSci Incorporated, USA). Again, these two bands couldptide sets
Possible protein matches
40S ribosomal protein S10 (sp|P63325)
60S ribosomal protein L22-like 1 (sp|Q9D7S7)
Histone H3-like centromeric protein A (sp|O35216)
Follistatin-related protein 4 (sp|Q5STE3)
H-2 class II histocompatibility antigen, A-D alpha chain (sp|P04228)
Metabotropic glutamate receptor 4 (sp|Q68EF4)
60s ribosomal protein L22-like 1 (sp|Q9D7S7)
Calcium/calmodulin-dependent protein kinase kinase 1 (sp|Q8VBY2)
40S ribosomal protein S9 (sp|Q6ZWN5)
C1q tumor necrosis factor-related protein 6 (sp|Q6IR41)
Histone H3-like centromeric protein A (sp|O35216)
Alpha-actinin-2 (sp|Q9JI91)
60S ribosomal protein L22 (sp|P67984)
Binding in the Cortex - 40X Binding the Amygdala – 40XShowing binding in 
Hippocampus  and all over 
mid brain areas - 40X
A B C
Hippocampus - 250 X
D
Cortex - 250X
E
Amygdala – 250X
F
CA3
CA3
TH
CTX
CA3LGd
Figure 8 Immunohistochemical staining using the brain of a control C3H/HeJ mouse and the serum of MRL/lpr #2. (A) Intense binding
detected all over the brain and the hippocampus. (B) and (C) showed binding in the cortex and amygdala, respectively (40× magnification).
(D), (E) and (F) showed binding in the hippocampus, cortex and amygdala at 250× magnification. Abbreviations: CA, hippocampal regions; LGd,
Dorsal part of the lateral geniculate complex; CTX, Cortex.
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Western blotting results of MRL/lpr #2 at approximately
97 kDa and 54 kDa.
For G10, we detected one band at ~69 kDa (Figure 9)
and saw low levels of binding all over the brain, but
greater binding was observed in the caudoputamen
(Figure 11B) and amygdala (Figure 11C). This band
could possibly be the leucine-rich repeat-containing
protein 4C. With BRAA G4, a band at ~69 kDa was seen
(Figure 9) and we saw binding in cortex (Figure 11D) and
the amygdala (Figure 11E) and lower levels of binding all
over the brain. This protein could possibly be GRB2-
associated-binding protein 2. Even though the targets of
G4 and G10 have the same apparent molecular weight,
based on the natural protein matches, their identity may
be different. With the serum of MRL/lpr #2, a band
at ~71 kDa was detected. This could be the same protein
detected by either G10 or G4. The only way to be sure is
to isolate the proteins and perform mass spectrometry.
Lastly, for F9, a band at ~158 kDa was detected (Figure 9)
and identified using the microarray as possibly being
synaptojanin-2. We saw low levels of binding all overthe brain, but greater binding was seen in the cortex
for F9 (Figure 11F). No non-specific binding was ob-
served on the secondary only or autofluorescence controls,
(Additional file 5: Figure S5A-H).
Discussion
Our goal was to characterize antibodies in three categories:
1) Diagnostic, 2) Predictive, and 3) Pathogenic. Diagnostic
(auto)antibodies may be reliably used for diagnosing a
specific disease. Predictive (auto)antibodies can predict
the future onset of that disease long before it occurs.
Finally, pathogenic (auto)antibodies are responsible for
pathogenic mechanisms in the disease causing symp-
tomatology. There is probably a good overlap between
these 3 categories, but they can also be different. Thus,
diagnostic antibodies need not be predictive (although
they can be), and vice versa. Likewise, pathogenic anti-
bodies need not be predictive, although they will almost
certainly be diagnostic.
Our first and second goals were to create a detection
kit that could diagnose and predict lupus and specific
CNS manifestations, using a unique high-throughput
D9
54 kD
39 kD
D1
95 kD
55 kD
158 kD
F9
69 kD
G10
69 kD
G4
~97 kD
~37 kD
LPR #2 NK -1R
45 kD
~71 kD
~54 kD
Figure 9 Western Blotting Results of the Monoclonal BRAA. Western blotting results showing the banding pattern of the five potential
pathogenic monoclonal BRAA, MRL/lpr #2 (mouse used to create the monoclonal BRAA) and the NK-1R positive control. Microsoft Office 2010
Picture Manager was used to adjust the brightness and contrast for some images.
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other studies to determine binding patterns specific to that
disease, such as Alzheimer’s [16], and we expect that for
each disease there will be a different binding pattern that
could allow us to distinguish one illness from another
([32,33] and unpublished data). In the future, it would be
good to test our microarray technology on other auto-
immune diseases to ensure that our tests can distinguish
one autoimmune disease from another. Because of the
various CNS manifestations and the idea that certain auto-
antibodies are partly responsible for each manifestation,
differences in binding patterns may allow us to distinguish
between them in lupus patients.
To begin, we ran the same protocols in two different
studies because the first study identified possible diag-
nostic peptides of lupus and its CNS manifestations and
the second study further suggested which peptides may
indeed be diagnostic. At the end of Study 2, we identi-
fied 58 potential diagnostic peptides of lupus. Of more
interest was trying to identify possible diagnostic pep-
tides for specific CNS manifestations. Most MRL/lpr
mice will eventually develop lupus, but CNS manifesta-
tions differ from one mouse to another [1]. Looking spe-
cifically at the forced swim test, we identified 39 possible
diagnostic peptides of this altered behavior.
Since we were interested in predicting lupus, in Study
1, we compared the 4 month MRL/mp to the C3H/HeJ
since we made the assumption that the MRL/mp would
not start developing lupus until 9–12 months of age andtherefore at 4 month of age should be pre-symptomatic
but having low levels of autoantibodies that are predict-
ive. We assumed that this was also the case for the
1.5 month MRL/lpr used in Study 2 since they would
not develop any symptoms until after 2 months of age.
Comparison of both studies identified 18 potential pre-
dictive peptides of lupus. For the forced swim test, we
identified 96 possible predictive peptides of this altered
behavior. To further narrow down the true number of
predictive peptides, we would need to run another study
and administer a comparison of the peptide sets. All
these diagnostic and predictive peptide sets only give us
indications of which peptides might in fact be diagnostic
and predictive, but further studies must be done to sup-
port these statements. We would need to run additional
test groups to validate our findings. In addition, these
studies and techniques give us useful methods and direc-
tions to pursue such supportive studies.
When selecting the peptides, we chose only the pep-
tides that were the highest binders; however, it would be
interesting in future studies to look at what the lower
binding peptides might be telling us. Also, for example,
when we selected peptides that may be diagnostic of al-
tered behavior in the forced swim test, we only selected
the 39 overlapping peptides between Studies 1 and 2
since diagnostic peptides should reappear from one
study to another, however, the non-overlapping peptides
were also high binders and therefore are still of interest
to us because some of the autoantibodies that are binding
Table 5 Possible natural protein matches for five
monoclonal BRAA
Monoclonal
antibody
Protein name
D1 MLX-interacting protein
D1 Endothelin B receptor
D1 Gamma-aminobutyric acid receptor subunit rho-1
D1 CAS1 domain-containing protein 1
D1 Disintegrin and metalloproteinase domain-containing
protein 1a
D1 Protein tweety homolog 3
G4 GRB2-associated-binding protein 2
G4 Diacylglycerol kinase epsilon
G4 Synaptotagmin-10
G4 Differentially expressed in FDCP 6
G4 Vesicular glutamate transporter 3
G4 Carbohydrate sulfotransferase 15
D9 Vacuolar protein sorting-associated protein 4B
D9 Transmembrane protein 164
D9 Cytohesin-1
D9 Galanin receptor type 3
D9 D(1B) dopamine receptor
D9 Fas apoptotic inhibitory molecule 2
F9 Serine/threonine-protein kinase TAO2
F9 Epidermal growth factor receptor
F9 Glutamate [NMDA] receptor subunit epsilon-3
F9 Nuclear pore complex protein Nup155
F9 Synaptojanin-2
F9 Astrotactin-1
G10 Autophagy-related protein 9A
G10 Leucine-rich repeat-containing protein 4C
G10 Matrix metalloproteinase-14 Alpha-1,3-mannosyl-glycoprotein
4-beta-N-acetylglucosaminyltransferase A
G10 N-acetylgalactosaminyltransferase 7
G10 Tyrosine-protein kinase Fyn
G10 Highlighted proteins are of interest.
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ation that we did not investigate.
Due to current inaccurate means of diagnosing lupus
and no methods to predict lupus, this microarray tech-
nology could help provide proper treatments, improve
patient care and add needed therapies. We tested this
technology in our mouse model first because this
allowed us to not only look at lupus but, of more inter-
est, determine if our technology could distinuguish one
CNS manifestation from another. Plus, we wanted to be
able to use these techniques in future studies to verify
pathogenic BRAA, by injecting the appropriate BRAAinto mice (which could not be done in human studies).
Another benefit of doing this study in mice first was that
we could obtain significant results with fewer samples as
in the case of Study 1. A limited set of mice were used
in the first study, but a larger number were used in the
second study. The purpose of the first study was simply
to identify some potential diagnostic peptides, so a large
number of mice were not needed. In addition, the statis-
tics were performed on measures that we were very cer-
tain would show differences (based on many previous
reports in the literature [34,35], including our own [2])
and, in fact, they did. The behavioral test and immuno-
logical assessments confirmed that the mice we were
using were indeed developing murine lupus as expected.
Also, with the mice, we could identify which will develop
lupus and CNS manifestations, whereas in human stud-
ies this would be difficult and we would need a tremen-
dously larger study to get the same information.
Finally, we have shown in previous studies [36] that
human sera can react with murine brain antigen. Thus,
we might use murine brain antigens as a diagnostic tool
for human CNS-lupus. We found that our microarrays
could identify antibody reactivity that demonstrated pre-
dictability of specific CNS manifestation in our mouse
model. It therefore seems likely that human lupus and
its CNS manifestations would also demonstrate a similar
trend, although we predict different peptides would be
found. Larger trials using human sera samples may de-
termine whether this is true. Expanded human trials
would allow us to determine how much personal vari-
ability or environmental influences exist in the lupus sig-
nature. Mice studies are constrained to clonal animals in
identical environments with identical histories. Humans
impose much more natural immunological variability.
Immunosignaturing has identified both predictive and
diagnostic peptides of autoimmune diseases such as dia-
betes [37], and therefore should be applicable to lupus.
Our third goal was to use the peptide sequences and
the Guitope computer analysis program to determine
possible natural protein matches, particularly for charac-
terizing the brain antigens which might be mediating
CNS manifestations [28]. When looking at the possible
diagnostic peptides of lupus, some matches were very in-
teresting since autoantibodies to some of these proteins
have been detected in lupus patients [38]. Autoanti-
bodies to the 60S ribosomal protein L12, which is im-
portant in protein synthesis, has been detected in 3-28%
of lupus patients [38]. Even though this protein is not
the 60S ribosomal subunit we detected, it is possible that
autoantibodies to our 60S ribosomal protein L22-like 1
can be affecting protein synthesis. Autoantibodies to 40S
ribosomal protein S10, which is also important in protein
synthesis, have been detected in 11-40% of lupus patients
[38]. The histone H3-like centromeric protein A, is like the
D9
Cortex – 250X Amygdala – 250X
Binding all over mid brain and 
Hippocampus – 40X
Hippocampus – 250X
A B
C D
CA3
CA3
TH
Figure 10 The brain of a C3H/HeJ mouse was incubated with the Monoclonal BRAA D9. (A) showed binding all over the brain. (B) displayed
binding in the hippocampus. (C) and (D) focused on binding in cortex and amygdala, respectively.
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DNA in the cell, and autoantibodies to this protein have
been detected in 50-90% of lupus patients [38,39]. These
anti-histones antibodies are thought to play a role in lupus
nephritis, which is one of the manifestations of lupus [38].
The exact mechanism that is occurring and how these
autoantibodies are altering body function is not known,
but these results help to suggest that these proteins are be-
ing affected during disease activity.
When looking at the possible predictive peptides of
lupus proteins of interest include C1q tumor necrosis
factor-related protein 6 and alpha-actinin-2. The collagen-
like region of C1q protein is believed to play a role in
lupus nephritis and autoantibodies to this protein occur in
about 30-50% of lupus patients [38]. Anti-alpha-actinin-2
antibodies have been detected in patients with lupus neph-
ritis [40]. It was interesting that these researchers detected
anti-alpha-actinin-2 antibodies even before lupus nephritis
was present. Autoantibodies to histone H3-like centro-
meric protein A and 60S ribosomal protein L22 were in
common with the diagnostic peptides of lupus, so these
autoantibodies may be present early on as biomarkers and
remain throughout the disease process. The metabotropic
glutamate receptor 4 was one of the possible natural pro-
tein matches for the potential diagnostic peptides of CNS
manifestations (altered behavior in the forced swim test).
Since researchers found that using an agonist to thisreceptor helped to decrease the float time in the forced
swim test, this glutamate receptor may play a role as an
anti-depressant in CNS-SLE [41].
To further identify potentially affected protein in
CNS-SLE we used MRL/lpr #2 from Study 2 to create
five monoclonal BRAA. Their possible protein matches
are listed in Table 4 and contain some interesting mole-
cules. For example, one possible target for D9 was the D
(1B) dopamine receptor, which is expressed in the limbic
system and plays a role in neurotransmission; therefore
any dysregulation of this receptor would likely result in
some neurological deficit, such as affecting memory
[42,43]. Other interesting matches include the gamma-
aminobutyric acid receptor subunit rho-1, which may play
a role in synaptic plasticity in the amygdala (an area of
the brain important in emotional dysfunction) [44]; the
leucine-rich repeat-containing protein 4C (MAb G10), also
known as Netrin-G1 ligand (NGL-1) [45], which may be
associated with schizophrenia, and schizophreniform-like
behavior is seen in CNS-SLE; the GRB2-associated-binding
protein 2 (MAb G4) may be involved in susceptibility to
Alzheimer disease [46]; and synaptojanin-2 (MAb F9),
which is important in the secretion of vesicles in the
synapse and any disruption would affect normal brain
functioning [47].
Future experiments, including the use of affinity
chromatography where the monoclonal BRAA would
D1
Caudoputamen – 250X
Fluorescence  all over 
Caudoputamen and Amygdala
G10
Caudoputamen - 250X Amygdala - 250X
A B C
G4
Cortex – Primary Auditory 
Area (Neocortex) - 250X
Amygdala - 250X
F9
Cortex – 250X
D E F
Figure 11 The above figures showed the binding pattern for the other four monoclonal BRAA D1, G10, G4 and F9. (A) showed binding
in caudoputamen for D1 (There was also binding in amygdala (not shown)). (B) and (C) showed binding in the caudoputamen and amygdala,
respectively for G10. (D) and (E) showed that for G4 there was binding in the cortex and the amygdala, respectively. (F) showed binding in the
cortex for F9.
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corresponding antigen from mouse brain homogenate,
should be employed. One could then identify the antigen
using mass spectrometry. These interesting experiments
are beyond the scope of the current study, however,
we have shown that our microarray technology allows
for further characterization of monoclonal BRAA. As a
strong test of the autoantibody hypothesis, confirming
the role of BRAA in CNS-SLE and the pathogenicity of
specific BRAA, it would be necessary to inject these
monoclonal BRAA in control mice and see if we can rep-
licate the behavioral dysfunctions.
BRAA are not the only mechanism for triggering CNS
involvement in SLE. As seen in Study1, when we split
the 4 month MRL/lpr into two groups based on their
anti-DNA autoantibody levels, it was noted that this
breakdown was the same as for the forced swim test
grouping. This suggests factors other than BRAA con-
tribute to the behavioral manifestations in the forced swim
test. However, higher anti-DNA autoantibody levels cannotdistinguish between several autoimmune diseases so the
hope is that the identified diagnostic and prognostic pep-
tides will be more specific to SLE, and more importantly,
the different CNS manifestations [48]. Of course, this will
need to be verified in future translational studies. A fur-
ther indication that anti-DNA autoantibody levels is not
the best diagnostic marker was seen in our sucrose pref-
erence test since the regrouping of the 4 M MRL/lpr
into low and high consumers were not the same as the
regrouping for the forced swim test or the anti-DNA auto-
antibody levels (data not included due to inconsistencies
across the two studies).
Genetics is a contributing factor to the development of
autoimmune diseases such as SLE [49,50]. The major
histocompatibility complex in humans (HLA), TNFα,
TNFβ, deficiency of complement components and IL10
are just a few examples of genes associated with SLE
[49,51]. Alterations in these genes can influence disease
onset and progression. The involvement of genetics on
the development of lupus-like disease in a mouse model,
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suppressed the autoimmune phenotype in male mice
[23]. Therefore the influence of such genetic elements
on the production of autoantibodies that promoted the
different banding patterns discovered using our microar-
rays need additional investigation. These studies would
create further understanding into the mechanisms pro-
moting the pathogenesis of SLE.
One very important asset of using our chip in predict-
ing and diagnosing lupus and its CNS manifestations is
its affordability, since this chip is created to be used for
any disease. There will be no need to develop a special-
ized chip just to detect lupus.
Conclusions
Overall, this random peptide microarray analysis was
able to identify both potential predictive and diagnostic
markers of lupus and altered behavior in the forced swim
test. This technology therefore looks promising as a de-
tection assay for lupus and its neuropsychiatric mani-
festations. More importantly, as shown above, it could
be used to give valuable information about pathogenic
mechanisms.Additional files
Additional file 1: Figure S2. Study 1- Behavioral Dysfunction (Forced
Swim Test). A significant difference in float time was detected (F = 12.068,
p < 0.008) and post-hoc analysis at p < 0.007 revealed that the 4 month
MRL/lpr had significantly greater float times compared to the MRL/mp
and C3H/HeJ.
Additional file 2: Figure S3. Study 1 – Group Separation within MRL/lpr
by Anti-DNA Autoantibody Levels. The 4 M MRL/lpr mice were also split
based on their anti-DNA antibody levels (grouping was similar to Figure 3).
There was a significant difference between the groups (F = 91.176, p < 0.001).
Utilizing post-hoc analysis at p < 0.004 there was a significant difference
between the 4 month MRL/lpr with greater anti-DNA autoantibody levels
and the 4 month MRL/lpr with lower anti-DNA autoantibody levels, the
MRL/mp and the C3H/HeJ. There was also a significant difference between
the MRL/lpr with lower anti-DNA autoantibody levels and the MRL/mp and
the C3H/HeJ.
Additional file 3: Figure S4. Study 2 - Behavioral Dysfunction (Forced
Swim Test). There was an overall significant difference between the
groups (F = 11.057, p < 0.001) and post-hoc analysis at p < 0.05 revealed
that the 4 M MRL/lpr floated significantly longer than the 1.5 M MRL/lpr,
1.5 M MRL/mp and 4 M MRL/mp. The 1.5 M MRL/mp was significantly
different from the 4 M MRL/mp.
Additional file 4: Figure S1. Sample peptide binding intensities across
pooled samples. This figure demonstrated the intensity pattern across
individual mice of different strains. Each green dot is the binding of
the serum to an individual peptide. (A) Secondary Only Control (only
secondary and tertiary antibodies added). (B) C3H/HeJ. (C) MRL/lpr
strain. (D) MRL/mp.
Additional file 5: Figure S5. Immunohistochemistry Control Slides. The
above (orange-yellow) fluorescence is from propidium iodide binding to
the cell nuclei. (A), (B), (C) and (D) showed that there was no binding in
most of the brain section, the hippocampus, cortex and amygdala for the
secondary only control. (E), (F), (G) and (H) showed that there was no
binding in the whole brain, hippocampus, cortex and amygdala for the
auto-fluorescence control.Abbreviations
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